The lack of ARG1 in the field of genetic metabolism is a questionable disease, clinical performance is complex and often involves multi-system congestion. Early identification and standardised clinical care are essential for improving prognosis. The diagnosis of ARG1 requires a comprehensive assessment platform such as clinical performance, imaging, laboratory testing, and pathological activation.
A team of authoritative experts at home and abroad can assist in providing accurate diagnosis and treatment. Treatment and management of ARG1 deficiencies require individual treatment regimens, usually including drug therapy, rehabilitation interventions, and regular follow-up dimension management. In recent years, with the development of treatment-oriented, immune-regulatory therapy and precision medicine, many previously difficult to treat genetic metabolic disorders have been significantly improved.
Treatment requires close monitoring of therapeutic effects and adverse reactions, adapting to timely schemes depending on the changes in the disease. Multidisciplinary collaboration (MDT) is particularly important for the comprehensive management of the lack of ARG1. 2.
Visiting China: arranging face-to-face treatment with authoritative experts, developing individualized treatment programs; 3. Full-service: providing one-stop services such as medical translation, medical care, accommodation arrangements; 4. Long-term follow-up: establishing a chronic disease management archive, continuous monitoring of changes in conditions and treatment effects.